This company listing is no longer active
Nichi-Iko Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Key information
-87.4%
Earnings growth rate
-86.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 2.6% |
| Return on equity | n/a |
| Net Margin | -87.7% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Nichi-Iko Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 182,880 | -160,439 | 29,073 | 4,772 |
| 30 Sep 22 | 184,379 | -145,208 | 28,125 | 4,655 |
| 30 Jun 22 | 183,179 | -105,407 | 27,867 | 5,173 |
| 31 Mar 22 | 179,060 | -104,984 | 27,879 | 4,248 |
| 31 Dec 21 | 184,265 | -19,667 | 27,116 | 4,029 |
| 30 Sep 21 | 184,518 | -18,918 | 27,438 | 4,275 |
| 30 Jun 21 | 185,896 | -8,246 | 27,196 | 4,349 |
| 31 Mar 21 | 188,218 | -4,179 | 27,029 | 4,335 |
| 31 Dec 20 | 186,759 | -606 | 26,589 | 4,246 |
| 30 Sep 20 | 188,188 | 2,273 | 25,708 | 4,040 |
| 30 Jun 20 | 188,818 | 3,610 | 25,628 | 3,749 |
| 31 Mar 20 | 190,076 | 5,133 | 25,614 | 4,261 |
| 31 Dec 19 | 181,530 | 5,482 | 24,173 | 3,859 |
| 30 Sep 19 | 175,765 | 5,250 | 23,869 | 3,688 |
| 30 Jun 19 | 170,837 | 6,216 | 23,333 | 3,571 |
| 31 Mar 19 | 166,592 | 6,864 | 22,504 | 3,503 |
| 31 Dec 18 | 148,475 | 9,317 | -981 | 7,065 |
| 30 Sep 18 | 152,766 | 10,241 | 7,759 | 6,382 |
| 30 Jun 18 | 158,482 | 8,567 | 15,484 | 5,687 |
| 31 Mar 18 | 164,717 | 8,070 | 23,136 | 4,467 |
| 31 Dec 17 | 189,563 | 7,388 | 46,047 | 7,263 |
| 30 Sep 17 | 182,518 | 5,059 | 43,855 | 7,263 |
| 30 Jun 17 | 173,856 | 4,752 | 42,584 | 7,263 |
| 31 Mar 17 | 163,372 | 4,788 | 40,112 | 7,263 |
| 31 Dec 16 | 152,468 | 3,647 | 40,882 | 4,874 |
| 30 Sep 16 | 149,677 | 9,595 | 38,837 | 4,874 |
| 30 Jun 16 | 146,493 | 10,736 | 36,631 | 4,874 |
Quality Earnings: 4541 is currently unprofitable.
Growing Profit Margin: 4541 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4541 is unprofitable, and losses have increased over the past 5 years at a rate of 87.4% per year.
Accelerating Growth: Unable to compare 4541's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4541 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.6%).
Return on Equity
High ROE: 4541's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.